source
- Ultragenyx’s Angelman therapy fails Phase 3, stock drops over 43% and company announces strategic reviewUltragenyx reported that its investigational Angelman syndrome drug apazunersen did not meet the primary cognitive endpoints in a Phase 3 trial. The lack of efficacy means the therapy will not prov…
- Summit and Akeso's ivonescimab beats Merck's Keytruda in Chinese NSCLC trialSummit Therapeutics and Akeso reported that their bispecific PD-1/VEGF antibody ivonescimab outperformed Merck's Keytruda in a Phase 3 HARMONi-2 trial conducted in China. The study enrolled first‑l…